Systematic Backbone Conformational Constraints on a Cyclic Melanotropin Ligand Leads to Highly Selective Ligands for Multiple Melanocortin Receptors

Minying Cai, Udaya Kiran Marelli, Jennifer Bao, Johannes G. Beck, Florian Opperer, Florian Rechenmacher, Kaitlyn R. McLeod, Morgan R. Zingsheim, Lucas Doedens, Horst Kessler, Victor J Hruby

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Human melanocortin receptors (hMCRs) have been challenging targets to develop ligands that are explicitly selective for each of their subtypes. To modulate the conformational preferences of the melanocortin ligands and improve the biofunctional agonist/antagonist activities and selectivities, we have applied a backbone N-methylation approach on Ac-Nle-c[Asp-His-d-Nal(2′)-Arg-Trp-Lys]-NH<inf>2</inf> (Ac-Nle<sup>4</sup>-c[Asp<sup>5</sup>,d-Nal(2′)<sup>7</sup>,Lys<sup>10</sup>]-NH<inf>2</inf>), a nonselective cyclic peptide antagonist at hMC3R and hMC4R and an agonist at hMC1R and hMC5R. Systematic N-methylated derivatives of Ac-Nle<sup>4</sup>-c[Asp<sup>5</sup>,d-Nal(2′)<sup>7</sup>,Lys<sup>10</sup>]-NH<inf>2</inf>, with all possible backbone N-methylation combinations, have been synthesized and examined for their binding and functional activities toward melanocortin receptor subtypes 1, 3, 4, and 5 (hMCRs). Several N-methylated analogues are selective and potent agonists or antagonists for hMC1R or hMC5R or have selective antagonist activity for hMC3R. The selective hMC1R ligands show strong binding for human melanoma cells. We have also discovered the first universal antagonist (compound 19) for all subtypes of hMCRs. (Figure Presented).

Original languageEnglish (US)
Pages (from-to)6359-6367
Number of pages9
JournalJournal of Medicinal Chemistry
Volume58
Issue number16
DOIs
StatePublished - Aug 27 2015

Fingerprint

Melanocortin Receptors
Melanocyte-Stimulating Hormones
Ligands
Methylation
Receptor, Melanocortin, Type 1
Melanocortins
Cyclic Peptides
Melanoma

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Systematic Backbone Conformational Constraints on a Cyclic Melanotropin Ligand Leads to Highly Selective Ligands for Multiple Melanocortin Receptors. / Cai, Minying; Marelli, Udaya Kiran; Bao, Jennifer; Beck, Johannes G.; Opperer, Florian; Rechenmacher, Florian; McLeod, Kaitlyn R.; Zingsheim, Morgan R.; Doedens, Lucas; Kessler, Horst; Hruby, Victor J.

In: Journal of Medicinal Chemistry, Vol. 58, No. 16, 27.08.2015, p. 6359-6367.

Research output: Contribution to journalArticle

Cai, Minying ; Marelli, Udaya Kiran ; Bao, Jennifer ; Beck, Johannes G. ; Opperer, Florian ; Rechenmacher, Florian ; McLeod, Kaitlyn R. ; Zingsheim, Morgan R. ; Doedens, Lucas ; Kessler, Horst ; Hruby, Victor J. / Systematic Backbone Conformational Constraints on a Cyclic Melanotropin Ligand Leads to Highly Selective Ligands for Multiple Melanocortin Receptors. In: Journal of Medicinal Chemistry. 2015 ; Vol. 58, No. 16. pp. 6359-6367.
@article{499366820c5c4af6a9b68a9029142b9a,
title = "Systematic Backbone Conformational Constraints on a Cyclic Melanotropin Ligand Leads to Highly Selective Ligands for Multiple Melanocortin Receptors",
abstract = "Human melanocortin receptors (hMCRs) have been challenging targets to develop ligands that are explicitly selective for each of their subtypes. To modulate the conformational preferences of the melanocortin ligands and improve the biofunctional agonist/antagonist activities and selectivities, we have applied a backbone N-methylation approach on Ac-Nle-c[Asp-His-d-Nal(2′)-Arg-Trp-Lys]-NH2 (Ac-Nle4-c[Asp5,d-Nal(2′)7,Lys10]-NH2), a nonselective cyclic peptide antagonist at hMC3R and hMC4R and an agonist at hMC1R and hMC5R. Systematic N-methylated derivatives of Ac-Nle4-c[Asp5,d-Nal(2′)7,Lys10]-NH2, with all possible backbone N-methylation combinations, have been synthesized and examined for their binding and functional activities toward melanocortin receptor subtypes 1, 3, 4, and 5 (hMCRs). Several N-methylated analogues are selective and potent agonists or antagonists for hMC1R or hMC5R or have selective antagonist activity for hMC3R. The selective hMC1R ligands show strong binding for human melanoma cells. We have also discovered the first universal antagonist (compound 19) for all subtypes of hMCRs. (Figure Presented).",
author = "Minying Cai and Marelli, {Udaya Kiran} and Jennifer Bao and Beck, {Johannes G.} and Florian Opperer and Florian Rechenmacher and McLeod, {Kaitlyn R.} and Zingsheim, {Morgan R.} and Lucas Doedens and Horst Kessler and Hruby, {Victor J}",
year = "2015",
month = "8",
day = "27",
doi = "10.1021/acs.jmedchem.5b00102",
language = "English (US)",
volume = "58",
pages = "6359--6367",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "16",

}

TY - JOUR

T1 - Systematic Backbone Conformational Constraints on a Cyclic Melanotropin Ligand Leads to Highly Selective Ligands for Multiple Melanocortin Receptors

AU - Cai, Minying

AU - Marelli, Udaya Kiran

AU - Bao, Jennifer

AU - Beck, Johannes G.

AU - Opperer, Florian

AU - Rechenmacher, Florian

AU - McLeod, Kaitlyn R.

AU - Zingsheim, Morgan R.

AU - Doedens, Lucas

AU - Kessler, Horst

AU - Hruby, Victor J

PY - 2015/8/27

Y1 - 2015/8/27

N2 - Human melanocortin receptors (hMCRs) have been challenging targets to develop ligands that are explicitly selective for each of their subtypes. To modulate the conformational preferences of the melanocortin ligands and improve the biofunctional agonist/antagonist activities and selectivities, we have applied a backbone N-methylation approach on Ac-Nle-c[Asp-His-d-Nal(2′)-Arg-Trp-Lys]-NH2 (Ac-Nle4-c[Asp5,d-Nal(2′)7,Lys10]-NH2), a nonselective cyclic peptide antagonist at hMC3R and hMC4R and an agonist at hMC1R and hMC5R. Systematic N-methylated derivatives of Ac-Nle4-c[Asp5,d-Nal(2′)7,Lys10]-NH2, with all possible backbone N-methylation combinations, have been synthesized and examined for their binding and functional activities toward melanocortin receptor subtypes 1, 3, 4, and 5 (hMCRs). Several N-methylated analogues are selective and potent agonists or antagonists for hMC1R or hMC5R or have selective antagonist activity for hMC3R. The selective hMC1R ligands show strong binding for human melanoma cells. We have also discovered the first universal antagonist (compound 19) for all subtypes of hMCRs. (Figure Presented).

AB - Human melanocortin receptors (hMCRs) have been challenging targets to develop ligands that are explicitly selective for each of their subtypes. To modulate the conformational preferences of the melanocortin ligands and improve the biofunctional agonist/antagonist activities and selectivities, we have applied a backbone N-methylation approach on Ac-Nle-c[Asp-His-d-Nal(2′)-Arg-Trp-Lys]-NH2 (Ac-Nle4-c[Asp5,d-Nal(2′)7,Lys10]-NH2), a nonselective cyclic peptide antagonist at hMC3R and hMC4R and an agonist at hMC1R and hMC5R. Systematic N-methylated derivatives of Ac-Nle4-c[Asp5,d-Nal(2′)7,Lys10]-NH2, with all possible backbone N-methylation combinations, have been synthesized and examined for their binding and functional activities toward melanocortin receptor subtypes 1, 3, 4, and 5 (hMCRs). Several N-methylated analogues are selective and potent agonists or antagonists for hMC1R or hMC5R or have selective antagonist activity for hMC3R. The selective hMC1R ligands show strong binding for human melanoma cells. We have also discovered the first universal antagonist (compound 19) for all subtypes of hMCRs. (Figure Presented).

UR - http://www.scopus.com/inward/record.url?scp=84940535833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940535833&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.5b00102

DO - 10.1021/acs.jmedchem.5b00102

M3 - Article

C2 - 26218460

AN - SCOPUS:84940535833

VL - 58

SP - 6359

EP - 6367

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 16

ER -